ClinicalTrials.gov
public full text
Public Domain
Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
This is a phase 3 study. Patients will be enrolled from 14 medical centers in mainland China. Eligible patients will be randomly allocated to treatment group (tobramycin nebulization, 300mg bid) and control group (natural saline nebulization, 5ml bid). A total of two 28-day on-and-off cycles will be scheduled. Both tobramycin solution and natural saline and the nebulizer will be solely provided by the sponsor.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Symptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials.#1039973
- Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis#1057655
- Evaluation of Medical and Nursing Management for Bronchiectasis#1162851
- Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis#127642
- A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis#1060772
Record · ID 1320483
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive